

Invitation to Participate **Multicenter Prospective Study**

**Sequential Intravesical Gemcitabine and Docetaxel for
High-Risk, BCG-Unresponsive NMIBC (GEMDOCE-BU)**

<https://clinicaltrials.gov/study/NCT07322263>

Principal Investigator:

Michael A. O'Donnell, MD

Director of Urologic Oncology, University of Iowa

Sub-Investigator:

Mohamad Abou Chakra, MD

Urologic Oncology Fellow

Dear Colleagues,

We are pleased to announce the opening of an international multicenter Phase II trial evaluating **sequential intravesical gemcitabine and docetaxel (Gem/Doce)** for patients with **high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)**.

We invite interested institutions to join this collaborative effort to advance bladder cancer research and expand access to innovative treatment options for patients worldwide.

Why Participate?

- ✓ Contribute to a landmark international NMIBC study
- ✓ Collaborate with leading bladder cancer investigators
- ✓ Provide patients access to a promising bladder-preserving therapy
- ✓ Help shape future standards of care for BCG-unresponsive NMIBC

 **Interested in Participating?** 

For the study protocol, site requirements, or additional information,
please contact:

GemDoce-BU-Trial@uiowa.edu

We look forward to collaborating with you on this important initiative.

University of Iowa Urologic Oncology Research Team
